Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide safety study in hospitalized patients with COVID-19 pneumonia
RBR-8vyvnmbPhase 2Not yet recruiting
- Sponsor
- Federal University of São Paulo
- Start
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liraglutide in coronavirus pneumonia, sponsored by Federal University of São Paulo. Primary endpoint: Safety of liraglutide use. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on RBR-8vyvnmb.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8vyvnmb.